Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Immune modulatory nanoparticle therapeutics for intracerebral glioma.

Yaghi NK, Wei J, Hashimoto Y, Kong LY, Gabrusiewicz K, Nduom EK, Ling X, Huang N, Zhou S, Kerrigan BC, Levine JM, Fajt VR, Levine G, Porter BF, Marcusson EG, Tachikawa K, Chivukula P, Webb DC, Payne JE, Heimberger AB.

Neuro Oncol. 2017 Mar 1;19(3):372-382. doi: 10.1093/neuonc/now198.

2.

Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy.

Kim DG, Kim KH, Seo YJ, Yang H, Marcusson EG, Son E, Lee K, Sa JK, Lee HW, Nam DH.

Oncotarget. 2016 May 17;7(20):29400-11. doi: 10.18632/oncotarget.8837.

3.

Shift of microRNA profile upon orthotopic xenografting of glioblastoma spheroid cultures.

Halle B, Thomassen M, Venkatesan R, Kaimal V, Marcusson EG, Munthe S, Sørensen MD, Aaberg-Jessen C, Jensen SS, Meyer M, Kruse TA, Christiansen H, Schmidt S, Mollenhauer J, Schulz MK, Andersen C, Kristensen BW.

J Neurooncol. 2016 Jul;128(3):395-404. doi: 10.1007/s11060-016-2125-x. Epub 2016 Apr 11.

PMID:
27063952
4.

Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept.

Halle B, Marcusson EG, Aaberg-Jessen C, Jensen SS, Meyer M, Schulz MK, Andersen C, Kristensen BW.

J Neurooncol. 2016 Jan;126(1):47-55. doi: 10.1007/s11060-015-1947-2. Epub 2015 Oct 1.

PMID:
26428358
5.

Anti-miRs competitively inhibit microRNAs in Argonaute complexes.

Hogan DJ, Vincent TM, Fish S, Marcusson EG, Bhat B, Chau BN, Zisoulis DG.

PLoS One. 2014 Jul 3;9(7):e100951. doi: 10.1371/journal.pone.0100951. eCollection 2014.

6.

Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis.

Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, Wang SE.

Cancer Cell. 2014 Apr 14;25(4):501-15. doi: 10.1016/j.ccr.2014.03.007.

7.

Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer.

Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA, Alahari SK.

Cancer Res. 2013 May 1;73(9):2884-96. doi: 10.1158/0008-5472.CAN-12-2162. Epub 2013 Jan 21.

8.

Control of RNA processing by a large non-coding RNA over-expressed in carcinomas.

Lin R, Roychowdhury-Saha M, Black C, Watt AT, Marcusson EG, Freier SM, Edgington TS.

FEBS Lett. 2011 Feb 18;585(4):671-6. doi: 10.1016/j.febslet.2011.01.030. Epub 2011 Jan 23.

9.

Efficient in vivo microRNA targeting of liver metastasis.

Huynh C, Segura MF, Gaziel-Sovran A, Menendez S, Darvishian F, Chiriboga L, Levin B, Meruelo D, Osman I, Zavadil J, Marcusson EG, Hernando E.

Oncogene. 2011 Mar 24;30(12):1481-8. doi: 10.1038/onc.2010.523. Epub 2010 Nov 22.

PMID:
21102518
10.

hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy.

Elyakim E, Sitbon E, Faerman A, Tabak S, Montia E, Belanis L, Dov A, Marcusson EG, Bennett CF, Chajut A, Cohen D, Yerushalmi N.

Cancer Res. 2010 Oct 15;70(20):8077-87. doi: 10.1158/0008-5472.CAN-10-1313. Epub 2010 Oct 5.

11.

miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.

Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A.

Nat Med. 2010 Oct;16(10):1134-40. doi: 10.1038/nm.2227. Epub 2010 Sep 26.

12.

Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.

Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK.

Cancer Res. 2010 May 1;70(9):3494-504. doi: 10.1158/0008-5472.CAN-09-3251. Epub 2010 Apr 20.

13.

Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model.

Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW, Weinberg RA.

Nat Biotechnol. 2010 Apr;28(4):341-7. doi: 10.1038/nbt.1618. Epub 2010 Mar 28.

14.

Enhanced expression and shedding of receptor activator of NF-kappaB ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis.

Nannuru KC, Futakuchi M, Sadanandam A, Wilson TJ, Varney ML, Myers KJ, Li X, Marcusson EG, Singh RK.

Clin Exp Metastasis. 2009;26(7):797-808. doi: 10.1007/s10585-009-9279-2. Epub 2009 Jul 10.

PMID:
19590968
15.

STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.

Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, Matthews VB, Armes J, Bhathal PS, Hughes NR, Marcusson EG, Karras JG, Na S, Sedgwick JD, Hertzog PJ, Jenkins BJ.

J Clin Invest. 2008 May;118(5):1727-38. doi: 10.1172/JCI34944.

16.

Targeting the eukaryotic translation initiation factor 4E for cancer therapy.

Graff JR, Konicek BW, Carter JH, Marcusson EG.

Cancer Res. 2008 Feb 1;68(3):631-4. doi: 10.1158/0008-5472.CAN-07-5635. Review.

17.

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG.

J Clin Invest. 2007 Sep;117(9):2638-48.

18.

Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells.

Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG.

Cancer Res. 2007 Apr 15;67(8):3583-93.

19.

Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes.

Habens F, Lapham AS, Dallman CL, Pickering BM, Michels J, Marcusson EG, Johnson PW, Packham G.

Oncogene. 2007 Mar 22;26(13):1910-9. Epub 2006 Sep 18.

PMID:
16983335
20.

Competition for RISC binding predicts in vitro potency of siRNA.

Koller E, Propp S, Murray H, Lima W, Bhat B, Prakash TP, Allerson CR, Swayze EE, Marcusson EG, Dean NM.

Nucleic Acids Res. 2006;34(16):4467-76. Epub 2006 Aug 31.

21.

Identification of novel PPARgamma target genes in primary human adipocytes.

Perera RJ, Marcusson EG, Koo S, Kang X, Kim Y, White N, Dean NM.

Gene. 2006 Mar 15;369:90-9. Epub 2005 Dec 27.

PMID:
16380219
22.

MicroRNA-143 regulates adipocyte differentiation.

Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, Dean NM, Freier SM, Bennett CF, Lollo B, Griffey R.

J Biol Chem. 2004 Dec 10;279(50):52361-5. Epub 2004 Oct 25.

23.

Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.

Henry SP, Marcusson EG, Vincent TM, Dean NM.

Trends Pharmacol Sci. 2004 Oct;25(10):523-7. Review.

PMID:
15380936
24.

Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage.

Michels J, O'Neill JW, Dallman CL, Mouzakiti A, Habens F, Brimmell M, Zhang KY, Craig RW, Marcusson EG, Johnson PW, Packham G.

Oncogene. 2004 Jun 17;23(28):4818-27.

PMID:
15122313
25.

Use of antisense oligonucleotides in functional genomics and target validation.

Ravichandran LV, Dean NM, Marcusson EG.

Oligonucleotides. 2004 Spring;14(1):49-64. Review.

PMID:
15104896
26.

Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.

Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, Welcsh P, Welch PJ, Welte K, King MC, Barber JR, Wong-Staal F.

Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):130-5.

27.

Identification and validation of a gene involved in anchorage-independent cell growth control using a library of randomized hairpin ribozymes.

Welch PJ, Marcusson EG, Li QX, Beger C, Krüger M, Zhou C, Leavitt M, Wong-Staal F, Barber JR.

Genomics. 2000 Jun 15;66(3):274-83.

PMID:
10873382
28.

Preclinical and clinical pharmacology of antisense oligonucleotides.

Marcusson EG, Yacyshyn BR, Shanahan WR Jr, Dean NM.

Mol Biotechnol. 1999 Aug;12(1):1-11. Review.

PMID:
10554769
29.

Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli.

Taylor JK, Zhang QQ, Monia BP, Marcusson EG, Dean NM.

Oncogene. 1999 Aug 5;18(31):4495-504.

30.

Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.

Marcusson EG, Bhat B, Manoharan M, Bennett CF, Dean NM.

Nucleic Acids Res. 1998 Apr 15;26(8):2016-23.

31.
32.

Multiple pathways for vacuolar sorting of yeast proteinase A.

Westphal V, Marcusson EG, Winther JR, Emr SD, van den Hazel HB.

J Biol Chem. 1996 May 17;271(20):11865-70.

34.

Novel protein kinase/phosphatidylinositol 3-kinase complex essential for receptor-mediated protein sorting to the vacuole in yeast.

Stack JH, Herman PK, DeWald DB, Marcusson EG, Lin Cereghino J, Horazdovsky BF, Emr SD.

Cold Spring Harb Symp Quant Biol. 1995;60:157-70. No abstract available.

PMID:
8824388
35.

The sorting receptor for yeast vacuolar carboxypeptidase Y is encoded by the VPS10 gene.

Marcusson EG, Horazdovsky BF, Cereghino JL, Gharakhanian E, Emr SD.

Cell. 1994 May 20;77(4):579-86.

PMID:
8187177
36.

Characterization of the lysosomal cystine transport system in mouse L-929 fibroblasts.

Greene AA, Marcusson EG, Morell GP, Schneider JA.

J Biol Chem. 1990 Jun 15;265(17):9888-95.

37.

Diagnosis of cystinosis with use of placenta.

Smith ML, Clark KF, Davis SE, Greene AA, Marcusson EG, Chen YJ, Schneider JA.

N Engl J Med. 1989 Aug 10;321(6):397-8. No abstract available.

PMID:
2747783

Supplemental Content

Loading ...
Support Center